» Articles » PMID: 38673957

Identification of AURKA As a Biomarker Associated with Cuproptosis and Ferroptosis in HNSCC

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Apr 27
PMID 38673957
Authors
Affiliations
Soon will be listed here.
Abstract

Cuproptosis and ferroptosis represent copper- and iron-dependent forms of cell death, respectively, and both are known to play pivotal roles in head and neck squamous cell carcinoma (HNSCC). However, few studies have explored the prognostic signatures related to cuproptosis and ferroptosis in HNSCC. Our objective was to construct a prognostic model based on genes associated with cuproptosis and ferroptosis. We randomly assigned 502 HSNCC samples from The Cancer Genome Atlas (TCGA) into training and testing sets. Pearson correlation analysis was utilized to identify cuproptosis-associated ferroptosis genes in the training set. Cox proportional hazards (COX) regression and least absolute shrinkage operator (LASSO) were employed to construct the prognostic model. The performance of the prognostic model was internally validated using single-factor COX regression, multifactor COX regression, Kaplan-Meier analysis, principal component analysis (PCA), and receiver operating curve (ROC) analysis. Additionally, we obtained 97 samples from the Gene Expression Omnibus (GEO) database for external validation. The constructed model, based on 12 cuproptosis-associated ferroptosis genes, proved to be an independent predictor of HNSCC prognosis. Among these genes, the increased expression of aurora kinase A (AURKA) has been implicated in various cancers. To further investigate, we employed small interfering RNAs (siRNAs) to knock down AURKA expression and conducted functional experiments. The results demonstrated that AURKA knockdown significantly inhibited the proliferation and migration of HNSCC cells (Cal27 and CNE2). Therefore, AURKA may serve as a potential biomarker in HNSCC.

Citing Articles

Causal association between blood metabolites and head and neck cancer: butyrylcarnitine identified as an associated trait for cancer risk and progression.

Li Y, Chen Z, Huang Z, Wang J, Wang J, Lin L Hereditas. 2025; 162(1):36.

PMID: 40087718 DOI: 10.1186/s41065-025-00408-5.


Aurora kinase A expression in pleomorphic adenoma, adenoid cystic carcinoma, and mucoepidermoid carcinoma of salivary glands: an immunohistochemical study.

Zare R, Izadi L, Alarcon-Sanchez M, Taghva M, Ranjbar M BMC Oral Health. 2025; 25(1):89.

PMID: 39825351 PMC: 11740330. DOI: 10.1186/s12903-024-05276-5.


Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy.

Zhang S, Huang Q, Ji T, Li Q, Hu C Biomark Res. 2024; 12(1):130.

PMID: 39482784 PMC: 11529036. DOI: 10.1186/s40364-024-00677-8.


Identification of disulfidptosis- and ferroptosis-related transcripts in periodontitis by bioinformatics analysis and experimental validation.

Fu Y, Xu T, Guo M, Lv W, Ma N, Zhang L Front Genet. 2024; 15:1402663.

PMID: 39045324 PMC: 11263038. DOI: 10.3389/fgene.2024.1402663.

References
1.
Racle J, de Jonge K, Baumgaertner P, Speiser D, Gfeller D . Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6. PMC: 5718706. DOI: 10.7554/eLife.26476. View

2.
Raudenska M, Balvan J, Masarik M . Cell death in head and neck cancer pathogenesis and treatment. Cell Death Dis. 2021; 12(2):192. PMC: 7893032. DOI: 10.1038/s41419-021-03474-5. View

3.
Zhao C, Zhang Z, Jing T . A novel signature of combing cuproptosis- with ferroptosis-related genes for prediction of prognosis, immunologic therapy responses and drug sensitivity in hepatocellular carcinoma. Front Oncol. 2022; 12:1000993. PMC: 9562991. DOI: 10.3389/fonc.2022.1000993. View

4.
Yadav V, De S . An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. Brief Bioinform. 2014; 16(2):232-41. PMC: 4794615. DOI: 10.1093/bib/bbu002. View

5.
Cramer J, Burtness B, Le Q, Ferris R . The changing therapeutic landscape of head and neck cancer. Nat Rev Clin Oncol. 2019; 16(11):669-683. DOI: 10.1038/s41571-019-0227-z. View